RxDoctor Payments Data

John Minarcik, MD

Retina Specialist · Fairfax, VANPI 1750427555

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for retina specialist clinicians in VA, where the typical reported total is $1,967.

$805in general payments, 2019–2025

Across 27 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$178
  • Genentech, Inc.$150
  • Apellis Pharmaceuticals, Inc.$130
  • ANI Pharmaceuticals, Inc.$80
  • Astellas Pharma US Inc$74
  • Regeneron Healthcare Solutions, Inc.$57
  • plus $135 from 4 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 20th percentile of 41 retina specialist providers in Virginia.

See all retina specialist providers in Virginia

Medicare billing

Part B allowed, 2024
$1,156,677
Medicare patients
520
Services billed
12,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate12$418
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$287

Paid to pharmacies, not to this prescriber.

Other retina specialist in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →